SLC43A1 and cancer: In fact, these previously proposed transporters of oxaliplatin were not significantly altered under our CRISPR/Cas9 screening conditions (Fig. S5A) and had inconsistent variation upon LAT3 manipulation in LAT3KO and LAT3OE cells (Fig S5B), leading us to conclude that the regulation of platinum accumulation to mediate resistance is cancer-type specific.